Last Minute Flashcards
1
Q
Phenylephrine
(Neosynephrine)
Methoxamine
(Vasoxyl)
A
- Agent Type: α1-Adrenoceptor Agonists
- Therapeutic Use (↑↓ Use): Nasal decongestant, hypotension considered pressor agent, glaucoma (↑outflow).
- Action: Full agonist α1-receptors, little or no β-activity, activate PLC, ↑Ca ↑IP3.
- Note: Not commonly used for hypotension
2
Q
Clonidine
(Catapres)
Guanfacine
(Tenex)
A
- Agent Type: α2-Adrenoceptor Agonists
-
Therapeutic Use (↑↓ Use): Hypertension (CNS to
↓ sympathetic outflow), opioid withdrawal (↓severity) - Action: α2-agonists (inhibit AC, ↓cAMP), inhibits NE release, cross BBB.
- Adverse: Dry mouth, sedation, impotence, rebound HTN, bradycardia.
- Note: Need to discontinue gradually to prevent rebound HTN.
3
Q
Fenoldopam
(Corlopam)
A
- Agent Type: Adrenoceptor Agonists- Dopamine
- Therapeutic Use (↑↓ Use): HTN crisis (Acute HTN), renal failure.
- Action: Dopamine D1A-Receptor Agonist (activates AC, ↑cAMP)
- Adverse: Tachycardia, ↑ocular pressure, can ↓serum K
- Notes: Used short-term by IV infusion
4
Q
Tizanidine
(Zanaflex)
A
- Agent Type: α2-Adrenoceptor Agonists
- Therapeutic Use (↑↓ Use): Short-term muscle spasticity (ie. whiplash), multiple sclerosis
- Action: Alpha2-agonist (inhibits AC, ↓cAMP), inhibits NE release, crosses BBB. CYP1A2 substrate
- Adverse: Sedation, hypotension bradycardia, dry mouth.
5
Q
α-Methyl Dopa
(Aldomet)
A
- Agent Type: α2-Adrenoceptor Agonists
- Therapeutic Use (↑↓ Use): Hypertension (CNS, ↓outflow)
- Action: Prodrug → metabolizd to α-methyl-NE (α2-agonist (↓cAMP), inhibits NE release.
- Note: Very good safety profile as anti-HTN during pregnancy
-
Adverse: Sedation, bradycardia , may cause positive
direct Coombs test (RBC destruction), liver disease
6
Q
Dexmedetomidine
(Precedex)
A
- Agent Type: α2-Adrenoceptor Agonists
- Therapeutic Use (↑↓ Use): Premed surgical sedation
- Action: Alpha2-agonist (inhibits AC, ↓cAMP), ↓NE release, crosses BBB.
- Adverse: Hypotension, ↓HR (may cause sinus arrest)
- Note: Little respiratory depression. ↑use
7
Q
[-zosin]
- *Prazosin** (Minipress)
- *Terazosin** (Hytrin)
- *Doxazosin** (Cardura)
- *Tamsulosin (α1A-)** (Flomax)
A
- Agent Type: α1-Adrenoceptor Antagonists
- Therapeutic Use (↑↓ Use): Benign prostatic hyperplasia (BPH), HTN, HTN crisis, Raynaud’s D.
- Action: Selective, competitive α1-receptor blockers. Presynaptic α2-receptors unaffected → no reflex ↑HR (since α2-receptors operational). Tamsulosin α1A-selective.
- Contra-indication: c PDE5 inhibitors ie Sildenafil (marked ↓BP)
-
Adverse: Orthostatic (postural) hypotension, nasal
congestion. - Both CV: ↓BP s reflex tachycardia. EPI reversal (+α-blocker) → ↓BP c ↑HR
8
Q
Pindolol
(Visken)

A
- Agent Type: β-Adrenoceptor Antagonists
- Therapeutic Use (↑↓ Use): HTN, Angina
- Action: Non-Selective β-AR Antagonist, MSA (Membrane Stabilizing Activity), Intrinsic Sympathomimetic Activity (ISA)
- Adverse: See β-antagonist Slide
9
Q
Atenolol
(Tenormin)

A
- Agent Type: β-Adrenoceptor Antagonists
- Therapeutic Use (↑↓ Use): HTN, Angina, Arrythmias, MI
- Action: β1-Selective Antagonist, NO Intrinsic Sympathomimetic Activity (ISA), NO Local Anaesthetic Action.
- Notes: Low Lipid Solubility (ie, CNS Action), Contraindication- Pregnant
- Adverse: See β-antagonist Slide
10
Q
Esmolol
(Brevablock)

A
- Agent Type: β1-Adrenoceptor Antagonists
- Therapeutic Use (↑↓ Use): Arrythmias, [angina]
- Action: β1-Selective Antagonist, NO Intrinsic Sympathomimetic Activity (ISA), NO Local Anaesthetic Action.
- Notes: Very short acting (10 min), used for arrythmias that arise during surgery.
- Adverse: See β-antagonist Slide
14
Q
- *Imipramine** (Tofrani)
- *Amitriptyline** (Elavil)
A
-
Agent Type: Tricyclic antidepressants (TCAs)
(Inhibit neuronal uptake) - Therapeutic Use (↑↓ Use): Depression
- Action: Inhibition of neuronal uptake (Uptake, 70-80% NE removal) to enhance NE effect. High lipid solubility, cross BBB. CNS action. Have some M-receptor & α-receptor blocking activity. Important in cases of suicide attempt.
- Adverse: Suicide risk, arrhythmia, myocardial ischemia, tachycardia, dry mouth, blurred vision, anxiety, agitation, panic attacks, insomnia
- Notes: Also have sedative effect.
15
Q
Dopamine Antagonists (Antipsychotics)
- *Haloperidol** (Aloperidin, Brotopon, Haldol, Halosten, Linton)
- Chlorpromazine* (Thorazine, Largactil)
A
- Agent Type: Dopamine Antagonists (Antipsychotics)
- Therapeutic Use (↑↓ Use): Schizophrenia, severe anxiety, nausea, vomiting, aggressive episodes, vocal utterances of Tourette’s disorder.
- Action: Dopamine-receptor blockers (chlorpromazine less potent than haloperidol). Typical antipsychotics. Use generally replaced by atypical antipsychotics (ie. Aripiprazole (Abilify), Olanzapine (Zyprexa) which have absence of extrapyramidal SE (↓prolactin elevation).
- Adverse: Sedation, ↑ mortality in elderly c dementia-related psychosis, tachycardia, prolong QT interval, dyskinesis, ↑prolactin levels.
16
Q
Catechol-O-MethyTransferase (COMT) Inhibitors
[-capone]
- *Tolcapone** (Tasmar)
- *Entacapone** (Comtan)
A
- Agent Type: Catechol-O-MethyTransferase (COMT) Inhibitors
- Therapeutic Use (↑↓ Use): Parkinson’s Disease (usually reserved for last-line treatment)
- Action: Reversible inhibition of COMT to prevent peripheral metabolism of L-dopa to allow ↑CNS access. COMT is less important than MAO. It is in tissues other than neurons (extraneuronal).
-
Adverse: Hepatoxicity, liver failure, dyskinesia,
hypotension, nausea, dizziness, anxiety, sleep disorder - Notes: Unlike MAO inhibitors, it isn’t a concern c tyramine-rich food.
17
Q
Inamrinone
(Milrinone)
A
- Agent Type: PDE Inhibitor
- Therapeutic Use ( ↑↓ Use): Acute & Chronic HF
- Action: Inhibit PDE III → ↑ cAMP→ ↑CO; Chronic (↑ mortality)
18
Q
Bethanechol
(Urecholine)
A
- Agent Type: M-receptor agonists: Limited clinical use, wide-action.
- Therapeutic Use (↑↓ Use): Post-operative urinary retention, gut atony
- Actions: M2, M3 > M1. Resistant to AchE. Doesn’t cross BBB. Given SC or IM but not IV (Very Potent).
- Adverse: SLUDGE; Sweating, salivation, lacrimation, urination, diarrhea, abdominal cramps, vomiting, hypotension, bradycardia, miosis, bronchospasm.
19
Q
Pilocarpine (Ocusert-Pilo)
Carbachol (Carbacel)
Methacholine (Provocholine)
A
- Agent Type: M-receptor agonists: Limited clinical use, wide-action.
-
Pilocarpine:
- Therapeutic Use (↑↓ Use): DOC-Acute emergency glaucoma
- Actions: Muscarinic activity; Resistant to AchE. Alkaloid, high lipid solubility, cross BBB. ↑outflow.
-
Carbachol:
- Therapeutic Use (↑↓ Use): Glaucoma, if pilocarpine ineffective
- Actions: Muscarinic & some nicotinic activity; Resistant to AchE.
-
Methacholine
- Therapeutic Use (↑↓ Use): Ocular procedures
- Actions: Resistant to AchE. Does not cross BBB.
- Other Therapeutic Use (↑↓ Use): dry mouth (xerostomia), bronchial challenge.
- Adverse: SLUDGE; Sweating, salivation, lacrimation, urination, diarrhea, abdominal cramps, vomiting, hypotension, bradycardia, miosis, bronchospasm.
20
Q
Organophosphate
Echothiophate(Phospholine)
DFP (Isoflurophate)
Vx, Sarin, Soman (Nerve Gases)
A
- Agent Type: Irreversible Cholinesterase Inhibitors, Organophosphates, OGs
-
Echothiophate & DFP
- Therapeutic Use (↑↓ Use): Glaucoma (miosis, cycloplegia)
-
Nerve Gases
- Use (↑↓ Use): Military, classified many 1000s
- Actions: High lipid solubility, readily cross BBB, CNS actions.
- Adverse: SLUDGE; Sweating, salivation, lacrimation,urination, diarrhea, abdominal cramps, vomiting, miosis, hypertension/hypotension, bradycardia, bronchospasm.
- Toxicity treatment before aging: atropine + pralidoxime (2-PAM). AchE aging (DFP: 30-40 min, nerve g: sec/min)
- Note: Muscle weakness (due to depolarizing block on N-receptors, this action is not reversible).
21
Q
Scopolamine(Isopto-Hyosine)
Propantheline (Probanthine)
- Glycopyrolate* (Robinul, Glycate)
- Pirenzepine* (Gastrozepin)
A
-
Agent Type: Competitive, Muscarinic Receptor Antagonists
- Scopolamine: 3-7 days action; Use: Motion sickness, diarrhea, ↓ Secretions
- Propantheline: Probanthine, Quaternary Amine; Use: GI disorders ie, mild diarrhea, [peptic ulcer]
- Glycopyrolate: GI disorders ie, mild diarrhea, [peptic ulcer]
- Pirenzepine: Peptic Ulcer; M1 Selective
-
Adverse: ↓ Secretions, dry mouth, mydriasis, cycloplegia, constipation (↓ GI Activity), tachycardia, urine retention, hallucinations & excitation. Elderly more sensitive. Toxicity treatment c physostigmine (AchE inhibitor).
- Hot as hell (thermoregulation). Blind as a bat (cycloplegia). Dry as a bone (↓ Secretions). Mad as a hatter (unresponsive, CNS delirium). Red as a beet (erythematous; direct vasodilation).
22
Q
Benztropine
(Cogentin)
A
- Agent Type: Competitive, Muscarinic Receptor Antagonists
- Therapeutic Use (↑↓ Use): Parkinson’s Disease, esp drug induced (improve tremor & rigidity but not bradykinesia)
- Actions: Crosses BBB
-
Adverse: ↓ Secretions, dry mouth, mydriasis, cycloplegia, constipation (↓ GI Activity), tachycardia, urine retention, hallucinations & excitation. Elderly more sensitive. Toxicity treatment c physostigmine (AchE inhibitor).
- Hot as hell (thermoregulation). Blind as a bat (cycloplegia). Dry as a bone (↓ Secretions). Mad as a hatter (unresponsive, CNS delirium). Red as a beet (erythematous; direct vasodilation).
23
Q
Varenicline
(Chantix)
A
- Agent Type: Nicotinic Receptor Agonist
- Therapeutic Use (↑↓ Use): smoking cessation
-
Actions: Partial Agonist nicotinic receptors (ANS & NMJ).
- Alkaloid, not endogenous, high lipid solubility. Readily crosses BBB. Widespread body action. Activates stimulatory & reward pathways. Prolonged stimulation (high toxic) causes depolarizing block similar to succinylcholine.
- Adverse: ↑ Risk Depression, Suicide. Nausea
- Acute CV: ↑BP, ↑HR, ↑respiration, ↓appetite
24
Q
Mecamylamine
(Inversine)
A
- Agent Type: Ganglionic Nicotinic Receptor (Non-Competetive) N-receptor Antagonists
- Therapeutic Use (↑↓ Use): Resistant hypertension (drug of last resort)
- Actions: Non-competitive, ganglionic N-receptor antagonist. Not frontline agent, drug of last resort. Good lipid solubility crosses BBB. Orally active.
- Adverse: Widespread body action, many adverse side effects. Orthostatic (postural) hypotension, dizziness, ↓BP, ↑ HR, impotence, mydriasis, cycloplegia (blurred vision), constipation, urinary retention, muscle weakness, fatigue.
- Note: Effective orally & has CNS action
25
Q
Trimethaphan
(Arfonad)
A
- Agent Type: Ganglionic Nicotinic Receptor (Competetive) N-receptor Antagonists
- Therapeutic Use (↑↓ Use): Hypertensive Crisis (CNS origin), ↓ Blood Loss During Surgery
- Actions: Competitive, Ganglionic N-receptor Antagonist. No CNS Action.
- Adverse: Widespread body action, many adverse side effects. Orthostatic (postural) hypotension, dizziness, ↓ BP, ↑ HR, impotence, mydriasis, cycloplegia (blurred vision), constipation, urinary retention, muscle weakness, fatigue.
- Note: Short Duration (10-15 min), inactive orally